What is the clinical evidence from this study?

Study design: Review. Population: Patients with heart failure without diabetes across reduced, mildly reduced, and preserved ejection fraction phenotypes. Intervention: SGLT2 inhibitors (empagliflozin, dapagliflozin) vs. Placebo or standard of care. Primary outcome: Composite of cardiovascular death or heart failure hospitalization (or worsening heart failure) (HR 0.74 to 0.82 depending on trial, 95% CI e.g. 0.65-0.85 in DAPA-HF, 0.65-0.86 in EMPEROR-Reduced, p=<0.001 in major trials cited).

What does this research mean for the field?

SGLT2 inhibitors significantly reduce heart failure hospitalization in patients without diabetes. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To critically review and synthesize evidence regarding the pathophysiological mechanisms, clinical efficacy, and safety profile of SGLT2 inhibitors for managing heart failure in patients without diabetes.

March 2, 2026CureusOpen Access

Use of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure Without Diabetes

Q: What are the key findings of this study?

SGLT2 inhibitors reduced the composite of cardiovascular death or heart failure hospitalization by 18-26% (HR 0.74-0.82, p<0.001) in patients with heart failure without diabetes across ejection fraction phenotypes.

Q: What does this research mean for the field?

SGLT2 inhibitors significantly reduce heart failure hospitalization in patients without diabetes. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Q: What question did this study set out to answer?

To critically review and synthesize evidence regarding the pathophysiological mechanisms, clinical efficacy, and safety profile of SGLT2 inhibitors for managing heart failure in patients without diabetes.

View Full Paper

Ask AI

Bookmark

Key result

SGLT2 inhibitors cut CV death or HF hospitalization up to ~26% in non-diabetic HF across EFs.

HR 0.74 to 0.82 depending on trial
95% CI e.g. 0.65-0.85 in DAPA-HF, 0.65-0.86 in EMPEROR-Reduced
P<0.001 in major trials cited

Why the study?

Do SGLT2 inhibitors improve clinical outcomes in patients with heart failure without diabetes?

Design

Review

Authors

JVJeilyn Jiron VindasCosta Rican Department of Social Security MMMaynor Jose Lopez MendozaCosta Rican Department of Social Security MMMaría Jennifer Valle MenaMinisterio de Salud Pública

Discussion

Member takes

Implication

Supports SGLT2i as foundational HF therapy independent of diabetes; extends benefit across EF phenotypes.

Key Points

To critically review and synthesize evidence regarding the pathophysiological mechanisms, clinical efficacy, and safety profile of SGLT2 inhibitors for managing heart failure in patients without diabetes.
Synthesized mechanistic and clinical evidence from major randomized trials, including DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER.
Evaluated metabolic, hemodynamic, and anti-inflammatory pathways alongside cardiovascular and renal outcomes across reduced, mildly reduced, and preserved ejection fraction phenotypes.
SGLT2 inhibitors consistently reduce heart failure hospitalizations across reduced, mildly reduced, and preserved ejection fraction phenotypes irrespective of diabetes status.
Cardiovascular mortality reductions are most robust in heart failure with reduced ejection fraction, while improvements in morbidity and health-related quality of life occur across all phenotypes.
Myocardial benefits are mediated by substrate shifts toward fatty acids and ketone bodies, improved mitochondrial efficiency, and reductions in oxidative stress and maladaptive remodeling.

Structured PICO

Do SGLT2 inhibitors improve clinical outcomes in patients with heart failure without diabetes?

Population

Patients with heart failure without diabetes, encompassing reduced, mildly reduced, and preserved ejection fraction phenotypes.

Intervention

SGLT2 inhibitors (including empagliflozin, dapagliflozin, and sotagliflozin) as a class, added to guideline-directed medical therapy.

Main Result

Effect estimate: HR 0.74 to 0.82 depending on trial (95% CI e.g. 0.65-0.85 in DAPA-HF, 0.65-0.86 in EMPEROR-Reduced)

p-value: p=<0.001 in major trials cited

SGLT2 inhibitors are foundational, disease-modifying therapies that provide significant cardiovascular benefits in heart failure patients independent of glycemic status.

Limitations

This is a narrative review without original primary data.
No meta-analytic or quantitative bias assessment was performed.
Heterogeneity of included studies is not quantitatively assessed.
No formal systematic review framework (e.g., PRISMA)
No duplicate independent screening process
No quantitative risk-of-bias synthesis

Cite This Study

Vindas et al. (2026) conducted a review in Patients with heart failure without diabetes across reduced, mildly reduced, and preserved ejection fraction phenotypes. SGLT2 inhibitors (empagliflozin, dapagliflozin) vs. Placebo or standard of care was evaluated on Composite of cardiovascular death or heart failure hospitalization (or worsening heart failure) (HR 0.74 to 0.82 depending on trial, 95% CI e.g. 0.65-0.85 in DAPA-HF, 0.65-0.86 in EMPEROR-Reduced, p=<0.001 in major trials cited). SGLT2 inhibitors reduced the composite of cardiovascular death or heart failure hospitalization by 18-26% (HR 0.74-0.82, p<0.001) in patients with heart failure without diabetes across ejection fraction phenotypes.

synapsesocial.com/papers/69a52920f1e85e5c73bf068e https://doi.org/10.7759/cureus.104397

Topics

SGLT2 inhibitors in heart failure HFrEF treatment Heart failure HFpEF management

View Full Paper

Ask AI

Bookmark

March 2, 2026CureusOpen Access

Use of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure Without Diabetes

View Full Paper

Ask AI

Bookmark

Key result

SGLT2 inhibitors cut CV death or HF hospitalization up to ~26% in non-diabetic HF across EFs.

HR 0.74 to 0.82 depending on trial
95% CI e.g. 0.65-0.85 in DAPA-HF, 0.65-0.86 in EMPEROR-Reduced
P<0.001 in major trials cited

Why the study?

Do SGLT2 inhibitors improve clinical outcomes in patients with heart failure without diabetes?

Design

Review

Authors

JVJeilyn Jiron VindasCosta Rican Department of Social Security MMMaynor Jose Lopez MendozaCosta Rican Department of Social Security MMMaría Jennifer Valle MenaMinisterio de Salud Pública

Discussion

Member takes

Implication

Supports SGLT2i as foundational HF therapy independent of diabetes; extends benefit across EF phenotypes.

Key Points

To critically review and synthesize evidence regarding the pathophysiological mechanisms, clinical efficacy, and safety profile of SGLT2 inhibitors for managing heart failure in patients without diabetes.
Synthesized mechanistic and clinical evidence from major randomized trials, including DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER.
Evaluated metabolic, hemodynamic, and anti-inflammatory pathways alongside cardiovascular and renal outcomes across reduced, mildly reduced, and preserved ejection fraction phenotypes.
SGLT2 inhibitors consistently reduce heart failure hospitalizations across reduced, mildly reduced, and preserved ejection fraction phenotypes irrespective of diabetes status.
Cardiovascular mortality reductions are most robust in heart failure with reduced ejection fraction, while improvements in morbidity and health-related quality of life occur across all phenotypes.
Myocardial benefits are mediated by substrate shifts toward fatty acids and ketone bodies, improved mitochondrial efficiency, and reductions in oxidative stress and maladaptive remodeling.

Structured PICO

Do SGLT2 inhibitors improve clinical outcomes in patients with heart failure without diabetes?

Population

Patients with heart failure without diabetes, encompassing reduced, mildly reduced, and preserved ejection fraction phenotypes.

Intervention

SGLT2 inhibitors (including empagliflozin, dapagliflozin, and sotagliflozin) as a class, added to guideline-directed medical therapy.

Main Result

Effect estimate: HR 0.74 to 0.82 depending on trial (95% CI e.g. 0.65-0.85 in DAPA-HF, 0.65-0.86 in EMPEROR-Reduced)

p-value: p=<0.001 in major trials cited

SGLT2 inhibitors are foundational, disease-modifying therapies that provide significant cardiovascular benefits in heart failure patients independent of glycemic status.

Limitations

This is a narrative review without original primary data.
No meta-analytic or quantitative bias assessment was performed.
Heterogeneity of included studies is not quantitatively assessed.
No formal systematic review framework (e.g., PRISMA)
No duplicate independent screening process
No quantitative risk-of-bias synthesis

Cite This Study

synapsesocial.com/papers/69a52920f1e85e5c73bf068e https://doi.org/10.7759/cureus.104397

Topics

SGLT2 inhibitors in heart failure HFrEF treatment Heart failure HFpEF management

View Full Paper

Ask AI

Bookmark